Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...
Some of the Capital One offers mentioned below are not currently available. Terms apply to American Express benefits and offers. Visit americanexpress.com to learn more. There are a lot of perks that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback